X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...

Health and Media Minister Dr. Nalinda Jayatissa directed the newly appointed members of the Ayurvedic Drug and Product Regulatory Council to ...

If approved by the EMA, mavorixafor would be the first drug indicated for patients with WHIM syndrome in Europe, a population ...

EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for ...

The National Medicines Regulatory Authority (NMRA) has started verifying prices directly with global pharmaceutical manufacturers whenever it notices significant discrepancies between the rates quoted ...

Medicinal Chemistry Research Assistant at the University of Kansas, US. "Moreover, clinical trials of treatments targeting Aβ protein or its aggregates have only been modestly effective, prompting a ...

Trusted source of information on Environmental Health that includes articles, news, videos, animations, quizzes, calculators ...

VMD response to concerns raised following media reports of serious adverse events in cats administered Solensia. The VMD is aware of media reports and ...

The doctors who were dragged into the Dengvaxia cases remain hopeful that their pending cases will be dismissed after the ...

Doctors who were dragged into the Dengvaxia cases are hoping to get justice through the ongoing evaluation conducted by the Department of Justice regarding the remaining Dengvaxia cases.

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.